Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ironwood Pharmaceuticals Inc IRWD

Healthcare Biotechnology
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of... see more

Recent & Breaking News (NDAQ:IRWD)

Ironwood Pharmaceuticals to Host Second Quarter 2014 Investor Update Call

Business Wire July 7, 2014

Ironwood Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference

Business Wire June 5, 2014

Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., to Board of Directors

Business Wire June 4, 2014

Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2014 Healthcare Conference

Business Wire May 7, 2014

Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2014

Business Wire May 1, 2014

Ironwood Pharmaceuticals Provides First Quarter 2014 Investor Update

Business Wire April 29, 2014

Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS®

Business Wire April 10, 2014

Ironwood Pharmaceuticals to Host First Quarter 2014 Investor Update Call

Business Wire April 8, 2014

Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease

Business Wire March 18, 2014

Ironwood Pharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference

Business Wire February 24, 2014

Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing

GlobeNewswire February 18, 2014

Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing

Thomson Reuters ONE February 18, 2014

Ironwood Pharmaceuticals Announces Exercise of Underwriters' Option in Public Offering of Common Stock

Business Wire February 13, 2014

Ironwood Pharmaceuticals Appoints Julie McHugh to Board of Directors

Business Wire February 12, 2014

Ironwood Pharmaceuticals Prices Public Offering of Common Stock

Business Wire February 11, 2014

Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock

Business Wire February 10, 2014

Ironwood Receives Notice of Allowance for Methods of Use Formulation Patent Expected to Extend LINZESS® Patent Protection Through 2031

Business Wire February 10, 2014

Ironwood Pharmaceuticals to Present at Leerink Global Healthcare Conference

Business Wire February 7, 2014

Ironwood Pharmaceuticals Provides Fourth Quarter 2013 Investor Update

Business Wire January 21, 2014

Ironwood Pharmaceuticals Announces Alignment of Workforce with Priority Growth Platforms

Business Wire January 8, 2014